



Abu Dhabi Thyroid Cancer - Surgical and Innovation Perspectives

This activity was designated for 4.00 AMA PRA Category 1 Credit™

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TIME ZONE EST GST	TOPIC	SPEAKER
08:00 - 08:10 16:00 - 16:10	Opening Remarks	Dr. Mahdi Shkoukani Dr. Samer El-Kaissi Dr. Greg Randolph
MODULE 1: New Technologies in Thyroidology		
08:10 - 08:25 16:10 - 16:25	Radiofrequency Ablation for Thyroid Nodules and Thyroid Cancer	KEYNOTE LECTURE Dr. Emad Kandil
08:25 - 09:10 16:25 - 17:10	PANEL Moderators Dr. Lindsay Bischoff Dr. Marika Russell RFA, Neural Monitoring, Parathyroid Autofluorescence	Panelists Dr. Dana Hartl Dr. Emad Kandil Dr. Juan Pablo Pantoja Dr. Mahdi Shkoukani Dr. Neil Tolley Dr. Samer El-Kaissi
MODULE 2: Thyroid Cancer Management 2024		
09:10 - 09:30 17:10 - 17:30	Oncocytic Carcinoma 2024 MSK Unique Molecular Alterations	Dr. Ian Ganly
09:30 - 09:50 17:30 - 17:50	MSK Redifferentiation for Advanced Thyroid Cancers 2024	Dr. Lori Wirth
09:50 - 10:40 17:50 - 18:40	PANEL Moderators Dr. David Shonka Dr. Sarimar Agosta Thyroid Cancers <ul style="list-style-type: none"> Differentiated Thyroid Cancer (DTC) Oncocytic Cell Carcinoma (OCC) Medullary Thyroid Cancer (MTC) Anaplastic Thyroid Cancer (ATC) 	Panelists Dr. David Grossman Dr. Hammad Hussain Dr. Hussein Saadi Dr. Ian Ganly Dr. Jatin Shah Dr. Lindsay Bischoff Dr. Lori Wirth
BREAK 10:40 - 11:00 18:40 - 19:00		
MODULE 3: Tumor Board		
11:00 - 11:20 19:00 - 19:20	Harvard TKI and Advanced Cancer Treatment 2024	KEYNOTE LECTURE Dr. Lori Wirth
11:20 - 11:40 19:20 - 19:40	Harvard Neoadjuvant Therapy Prior to Advanced Cancer Surgery	SUPPORTING LECTURE Dr. Greg Randolph
11:40 - 12:30 19:40 - 20:30	PANEL Moderators Dr. Greg Randolph Dr. Jeremy Freeman Tumor Board	Panelists Dr. Ashok Shaha Dr. Lori Wirth Dr. Mahdi Shkoukani Dr. Marcin Barczynski Dr. Naveed Ahmed Dr. Samer El-Kaissi Dr. Sarimar Agosto

ADJOURN

The planning committee, faculty, and others in control of content (either individually or as a group) have NO relevant financial relationship(s) to disclose with ineligible companies.